MedTrace Logo

Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer

NCT02529579 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2015-08-20

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.

Conditions

  • Carcinoma, Pancreatic Ductal

Interventions

OTHER

iAPA-DC/CTL adoptive cellular immunotherapy

twice DC cell infusion and CTL cell infusion for 6 times

DRUG

Gemcitabine

standard Gemcitabine therapy

Sponsors & Collaborators

  • ImmunoGene Biotechology Co.,Ltd

    collaborator UNKNOWN

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhaoshen Ii, MD · Changhai Hosptial,Second Military medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02529579 on ClinicalTrials.gov